Chain Drug Review - Evista granted priority review
Eli Lilly and Co. says that the FDA has granted a priority review for the supplemental new drug application for an osteoporosis indication for Evista. The drug has been on the market since January 1998 for use in preventing osteoporosis in postmenopausal women.
Related Results
Evista approvalResearch on EvistaMarketing of Lilly’s Evista investigatedLilly Ups Support for EvistaLilly’s Evista builds bone
COPYRIGHT 1999 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
